Article Synopsis

  • There is significant variability in muscle growth (hypertrophy) among individuals following resistance exercise, but the exact reasons are not fully understood.
  • A study analyzed various hormones related to muscle growth before and after 12 weeks of resistance exercise in trained men, but no individual hormone showed a consistent link to muscle growth across participants.
  • The findings suggest that the content of androgen receptors within muscle may be more important for muscle mass increases than circulating hormones, as higher receptor levels correlated with greater gains in muscle size.

Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The factors that underpin heterogeneity in muscle hypertrophy following resistance exercise training (RET) remain largely unknown. We examined circulating hormones, intramuscular hormones, and intramuscular hormone-related variables in resistance-trained men before and after 12 weeks of RET. Backward elimination and principal component regression evaluated the statistical significance of proposed circulating anabolic hormones (e.g., testosterone, free testosterone, dehydroepiandrosterone, dihydrotestosterone, insulin-like growth factor-1, free insulin-like growth factor-1, luteinizing hormone, and growth hormone) and RET-induced changes in muscle mass ( = 49). Immunoblots and immunoassays were used to evaluate intramuscular free testosterone levels, dihydrotestosterone levels, 5α-reductase expression, and androgen receptor content in the highest- (HIR; = 10) and lowest- (LOR; = 10) responders to the 12 weeks of RET. No hormone measured before exercise, after exercise, pre-intervention, or post-intervention was consistently significant or consistently selected in the final model for the change in: type 1 cross sectional area (CSA), type 2 CSA, or fat- and bone-free mass (LBM). Principal component analysis did not result in large dimension reduction and principal component regression was no more effective than unadjusted regression analyses. No hormone measured in the blood or muscle was different between HIR and LOR. The steroidogenic enzyme 5α-reductase increased following RET in the HIR ( < 0.01) but not the LOR ( = 0.32). Androgen receptor content was unchanged with RET but was higher at all times in HIR. Unlike intramuscular free testosterone, dihydrotestosterone, or 5α-reductase, there was a linear relationship between androgen receptor content and change in LBM ( < 0.01), type 1 CSA ( < 0.05), and type 2 CSA ( < 0.01) both pre- and post-intervention. These results indicate that intramuscular androgen receptor content, but neither circulating nor intramuscular hormones (or the enzymes regulating their intramuscular production), influence skeletal muscle hypertrophy following RET in previously trained young men.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189473PMC
http://dx.doi.org/10.3389/fphys.2018.01373DOI Listing

Publication Analysis

Top Keywords

androgen receptor
20
receptor content
20
muscle hypertrophy
12
principal component
12
free testosterone
12
type csa
12
skeletal muscle
8
young men
8
hormones intramuscular
8
intramuscular hormones
8

Similar Publications

Discovery of -(thiazol-2-yl) Furanamide Derivatives as Potent Orally Efficacious AR Antagonists with Low BBB Permeability.

J Med Chem

September 2025

State Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, China.

Resistance-conferring mutations in the androgen receptor (AR) ligand-binding pocket (LBP) compromise the effectiveness of clinically approved orthosteric AR antagonists. Targeting the dimerization interface pocket (DIP) of AR presents a promising therapeutic approach. In this study, we report the design and optimization of -(thiazol-2-yl) furanamide derivatives as novel AR DIP antagonists, among which was the most promising candidate.

View Article and Find Full Text PDF

ACP-105 (CAS: 1048998-11-3) is a novel non-steroidal selective androgen receptor modulator (SARM), increasingly detected in anti-doping analyses, yet lacking a comprehensive ADME profile. This study provides the first integrative in silico characterization of ACP-105's ADME properties using seven independent methods (ADMETlab 3.0, ADMET Predictor 12.

View Article and Find Full Text PDF

Analysis of the toxicity and mechanisms of osteoporosis caused by cigarette toxicants using network toxicology and molecular docking techniques.

Sci Total Environ

September 2025

Department of Orthopedics and Traumatology, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, Sichuan Province, China. Electronic address:

The objective of this research was to use a network toxicology approach to examine the possible toxicity of the cigarette toxicants nicotine and coal tar that cause osteoporosis (OP) as well as its molecular processes. We determined the primary chemical structures and 128 targets of action of tar and nicotine using the Swiss Target Prediction, NP-MRD, and PubChem databases. We discovered that genes including DNAJB1, CCDC8, LINC00888, ATP6V1G1, MPV17L2, PPCS, and TACC1 had a disease prognostic guiding value by LASSO analysis and differential analysis of GEO microarray data.

View Article and Find Full Text PDF

Human Kallikrein 2 (KLK2) is a prostate cancer tissue specific protein that is regulated by androgen receptor (AR) signaling. KLK2 was not previously recognized as a therapeutic target as it is secreted. It has now been demonstrated that KLK2 is expressed on the cell surface and targetable by various methodologies.

View Article and Find Full Text PDF

Do AR and TILs have any association with the efficacy of neoadjuvant treatment for HER2-positive breast cancer?

Medicine (Baltimore)

September 2025

Department of Breast Surgery, Weifang People's Hospital, Weifang, Shandong Province, People's Republic of China.

The presence of androgen receptor (AR) as a marker can be detected in all breast cancer subtypes, and it may provide information on treatment response and prognosis. This study aimed to examine the correlation between AR expression and treatment response in patients diagnosed with human epidermal growth factor receptor 2 (HER2) positive breast cancer who were undergoing neoadjuvant therapy (NAT). The evaluation included breast cancer patients who received NAT and underwent surgery at Weifang People's Hospital's Department of Breast Surgery between October 2019 and October 2022.

View Article and Find Full Text PDF